✦ LIBER ✦

Health-related outcomes associated with tapentadol extended release (ER) treatment for the management of painful diabetic peripheral neuropathy (DPN): results of a randomized-withdrawal phase 3 trial

✍ Scribed by Etropolski, M.; Kleinert, R.; Shapiro, D.Y.; Okamoto, A.; Lange, R.; Rauschkolb, C.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Sensitivity analyses of the primary effi

✍ Etropolski, M.; Steup, A.; Shapiro, D.Y.; Okamoto, A.; Haeussler, J. 📂 Article 📅 2009 🏛 Canadian Diabetes Association 🌐 English ⚖ 448 KB

Efficacy and tolerability of tapentadol

✍ A. Vinik; D. Shapiro; C. Rauschkolb-Löffler; B. Lange; K. Karcher; D. Pennett; M 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 38 KB

Health status (EuroQol-5 Dimension [EQ-5

✍ Okamoto, A.; Shapiro, D.Y.; Lange, B.; Lange, R.; Etropolski, M. 📂 Article 📅 2009 🏛 Canadian Diabetes Association 🌐 English ⚖ 435 KB

Poster 51: Health-related Outcomes Assoc

✍ Bettyanne McCann; Mila S. Etropolski; Jane S. Gilbert; Alison Greene; Brigitte K 📂 Article 📅 2009 🏛 Wiley (John Wiley & Sons) 🌐 English ⚖ 59 KB

PMS4 EUROQOL-5 DIMENSION HEALTH STATUS Q

✍ Kavanagh, S; Ashworth, J; Lange, B; Etropolski, MS; Van Hove, I; Rauschkolb, C 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 99 KB